Buprenorphine May Be Most Effective At Treating Neonatal Abstinence Syndrome: Study

New research highlights the continuing struggles to identify effective ways to address the growing number of infants born addicted to opioids and other drugs, but indicates that the pain killer buprenorphine is currently the best option to treat neonatal abstinence syndrome. 

Canadian researchers published a study in the medical journal JAMA Pediatrics on January 22, indicating that buprenorphine is the most effective pharmacological treatment so far for neonatal abstinence syndrome. However, researchers warn that there is a lack of good data and information.

Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome, which occurs primarily among infants after birth who were exposed to narcotic painkillers during pregnancy. While other drugs have been implicated in NAS, it is most often attributed to in utero opioid exposure.

Did You Know? Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

NAS can result from maternal prescription opioid use, opioid abuse, and medication-assisted treatment. The most common opioids abused include OxyContin, Vicodin, Percocet and fentanyl, as well as other illicit opioids, such as heroin.

In this latest study, researchers from Dalhousie University in Nova Scotia looked at data from 18 clinical trials, involving 1,072 babies born with NAS. They looked for how long treatment took, the length of hospital stays, adjuvant therapy and adverse events in the use.

Researchers found a number of drugs were used to ease the effects of drug addiction in infants, including buprenorphine, clonidine, diluted tincture of opium and clonidine, diluted tincture of opium, morphine, methadone and phenobarbital. Buprenorphine appeared to be associated with the shortest length of treatment and length of hospital stay; nearly 13 days shorter in treatment than morphine and resulting in nearly 12 fewer days for infants to be hospitalized.

“The current evidence suggests that buprenorphine is the optimal treatment for neonatal abstinence treatment, but limitations are considerable and wide-scale adoption requires a large multisite trial,” the researchers concluded. “Morphine, which is considered standard of care in most hospitals, was the lowest-ranked opioid for length of treatment and length of stay.”

The study comes about two years after the U.S. Centers for Disease Control and Prevention (CDC) first warned about increasing numbers of children born with opioid-induced NAS across the U.S.

That researched warned that cases of babies born addicted to opioids increased more than 300% from 1999 to 2013. The CDC warned that by 2013, there were six cases of neonatal abstinence syndrome for every 1,000 hospital births in the U.S.

1 Comments

  • JeremyMay 3, 2022 at 10:39 pm

    Buprenorphine has been wonderful, in the sense that I no longer doctor shop or pray that I can get to a pain clinic. However; I think in line with this article , I have lost a 'shit load of teeeth' since beginning this treatment.

"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Camp Lejeune Water Lawsuits Now Being Filed After President Biden Signed PACT Act
Camp Lejeune Water Lawsuits Now Being Filed After President Biden Signed PACT Act (Posted yesterday)

The President has signed the Camp Lejeune Justice Act into law as part of a larger package of veterans toxic chemical exposure health care benefits, which will allow those exposed to water contamination while living or serving on the base to file lawsuits against the federal government.